In the following year, phase III clinical trials brought great encouragement to the anti-EGFR therapy by suggesting that FOLFIRI plus cetuximab might be preferred for patients with metastatic colorectal cancer that is KRAS exon 2 wild-type (25). The gene discussed is KRAS; the disease is metastatic colorectal cancer.